Literature DB >> 15124691

G3139, a BCL-2 antisense oligo-nucleotide, in AML.

G Marcucci1, W Stock, G Dai, M I Klisovic, K Maharry, T Shen, S Liu, D A Sher, D Lucas, A Zwiebel, R A Larson, M A Caligiuri, C D Bloomfield, K K Chan, M R Grever, J C Byrd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15124691     DOI： 10.1007/s00277-004-0850-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  1 in total

1.  Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.

Authors:  Rebecca B Klisovic; William Blum; Zhongfa Liu; Zhiliang Xie; Cheryl Kefauver; Lenguyen Huynh; James A Zwiebel; Steven M Devine; John C Byrd; Michael R Grever; Kenneth K Chan; Guido Marcucci
Journal:  Leuk Lymphoma       Date:  2013-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.